Notebook

LIFE GOES ON: Francis Collins says he won't change his style. In an October 1 "Dear Colleague" letter to 100 or so leukemia genetics researchers, geneticist Francis Collins explained that he was retracting five research papers on leukemia in leading scientific journals because a junior colleague falsified data. News of the letter was originally reported in the Chicago Tribune on October 29 (J. Crewdson, page 1). Collins, director of the Human Genome Project and the National Center for Human Ge

| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

LIFE GOES ON: Francis Collins says he won't change his style. In an October 1 "Dear Colleague" letter to 100 or so leukemia genetics researchers, geneticist Francis Collins explained that he was retracting five research papers on leukemia in leading scientific journals because a junior colleague falsified data. News of the letter was originally reported in the Chicago Tribune on October 29 (J. Crewdson, page 1). Collins, director of the Human Genome Project and the National Center for Human Genome Research (NCHGR), part of the National Institutes of Health, told the Tribune that the junior scientist confessed to a "stunning series of data misrepresentations and outright fabrications extending over a period of at least two years." Collins found out about the fabrication in mid-August when a journal editor pointed out that an anonymous reviewer had raised questions about a manuscript he and the colleague, later identified by the New York ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies